RESEARCH ARTICLE

Differential Effects of β-Blockers, Angiotensin II Receptor Blockers, and a Novel AT2R Agonist NP-6A4 on Stress Response of Nutrient-Starved Cardiovascular Cells

Abuzar Mahmood1,3, Lakshmi Pulakat1,2,3*

1 Department of Medicine, University of Missouri, Columbia, MO, United States of America, 2 Department of Nutrition and Exercise Physiology, University of Missouri, Columbia, MO, United States of America, 3 Harry S. Truman Memorial Veterans’ Affairs Hospital, Columbia, MO, United States of America

* pulakatl@health.missouri.edu

Abstract

In order to determine differences in cardiovascular cell response during nutrient stress to different cardiovascular protective drugs, we investigated cell responses of serum starved mouse cardiomyocyte HL-1 cells and primary cultures of human coronary artery vascular smooth muscles (hCAVSMCs) to treatment with β-blockers (atenolol, metoprolol, carvedilol, nebivolol, 3 μM each), AT1R blocker losartan (1 μM) and AT2R agonists (CGP42112A and novel agonist NP-6A4, 300nM each). Treatment with nebivolol, carvedilol, metoprolol and atenolol suppressed Cell Index (CI) of serum-starved HL-1 cells (ΔC20 17%, ΔC20 8%, ΔC20 15% and ΔC20 15% respectively) as measured by the Xcelligence Real-Time Cell Analyzer (RTCA). Conversely, CI was increased by Ang II (ΔC21 9.6%), CGP42112A (ΔC21 14%), and NP-6A4 (ΔC21 25%) respectively and this effect was blocked by AT2R antagonist PD123319, but not by AT1R antagonist losartan. Thus, the CI signature for each drug could be unique. MTS cell proliferation assay showed that NP-6A4, but not other drugs, increased viability (ΔC21 20%) of HL-1 and hCAVSMCs. Wheat Germ Agglutinin (WGA) staining showed that nebivolol was most effective in reducing cell sizes of HL-1 and hCAVSMCs. Myeloid Cell Leukemia 1 (MCL-1) is a protein critical for cardiovascular cell survival and implicated in cell adhesion. β-blockers significantly suppressed and NP-6A4 increased MCL-1 expression in HL-1 and hCAVSMCs as determined by immunofluorescence. Thus, reduction in cell size and/or MCL-1 expression might underlie β-blocker-induced reduction in CI of HL-1. Conversely, increase in cell viability and MCL-1 expression by NP-6A4 through AT2R could have resulted in NP-6A4 mediated increase in CI of HL-1. These data show for the first time that activation of the AT2R-MCL-1 axis by NP-6A4 in nutrient-stressed mouse and human cardiovascular cells (mouse HL-1 cells and primary cultures of hCAVSMCs) might underlie improved survival of cells treated by NP-6A4 compared to other drugs tested in this study.
Introduction

Cardiovascular diseases, particularly ischemic heart disease, are the number one cause of death worldwide despite commendable advances in acute care and pharmacotherapy [1–4]. Cardiomyocyte death via necrosis, apoptosis and impaired autophagy are hallmarks of cardiac pathology associated with heart failure, myocardial infarction and ischemia/reperfusion injury [3–6]. Anti-hypertensive drugs such as β-adrenergic receptor blockers (β-blockers) and inhibitors of angiotensin II type 1 receptor (AT1R) are reported to exert cardioprotective effects by reducing cardiomyocyte death [7–11].

β-adrenergic receptor blockers (β-blockers) are the standard of care for myocardial infarction (MI) and ischemic heart disease. However, recent clinical trials have questioned the morbidity and mortality benefits of these drugs in the management of patients with cardiac disease [12–14]. Traditional contraindications for β-blockers include peripheral vascular diseases, diabetes mellitus, chronic obstructive pulmonary disease (COPD) and asthma [12–14]. The 2nd generation β-blockers atenolol (Aten) and metoprolol (Met) are more likely to worsen glucose tolerance and increase the risk of developing diabetes [15, 16]. The 3rd generation β-blockers carvedilol (Car) and nebivolol (Neb) are considered to be safer and more effective drugs since Car blocks the α-adrenergic receptor and improves vasodilation, and Neb activates the cardio-protective β-3 adrenergic receptor that results in activation of the AMP kinase (AMPK)-endothelial Nitric Oxide Synthase (eNOS) pathway [10,17–20]. Neb might function as a biased agonist and could reduce weight gain in rodents and humans [18–20]. We have shown recently that Neb–induced resistance to weight gain in leptin resistant rats involves the cardiac miR-208-MED13 axis [21]. However, further studies are needed to fully understand the protective effects of Neb compared to other β-blockers on cardiovascular cells subjected to nutrient stress.

Angiotensin II (Ang II) acting through the AT1R is an important contributor to vasoconstriction and promotes cardiac hypertrophy, fibrosis and heart disease [22, 23]. Moreover, AT1R activation induces adult cardiomyocyte cell death [24, 25]. AT1R blockers (ARBs) are another group of widely used drugs to treat patients with hypertension, atherosclerosis, coronary heart disease, restenosis, and heart failure. However, clinical trials have raised concerns regarding the potential of ARBs to increase risk of MI [26]. Unlike AT1R, activation of Ang II type 2 receptor (AT2R) causes vasodilation and improves cardiac repair after MI [27, 28]. We have shown that AT2R activation can inhibit AT1R-mediated inositol 1,4,5-triphosphate generation and that the 3rd intracellular loop of AT2R is required for this effect [29]. Though AT2R activation causes neonatal cardiomyocyte apoptosis, this effect is not seen in adult cardiomyocytes [30, 31]. However, signaling mechanisms of the AT2R are less defined compared to that of the AT1R and drugs that can act as specific AT2R agonists are still emerging.

Serum starvation that results in nutrient deficiency stress is an important factor associated with ischemic heart disease and contributes to significant loss of cardiovascular cells via cell death [32, 33]. To gain a better understanding of the potential of different cardioprotective drugs to improve cardiovascular cell survival during nutrient deficiency stress, we compared the effects of different cardioprotective drugs on cell survival of mouse cardiomyocyte HL-1 cells and primary cultures of human coronary artery vascular smooth muscle cells (hCAVSMCs) subjected to serum starvation. For studies on HL-1 cells, we used the xCELLigence RTCA (Real-Time Cell Analyzer), a system that provides an effective method to assess survival and adhesion properties of cells by obtaining real-time kinetic data that captures an accurate characterization of short-lived changes in cell size, number and adhesion [34,35]. This system measures real-time electrical impedance variations in microelectrodes at the base of 16-well microtiter “E-plates” and reports it in terms of cell index (CI). We hypothesized that although all drugs would protect adult cardiovascular cells from significant cell death, the CI
pattern or the “CI signature” generated by these drugs could be different and would help to explain which of these drugs most effectively renders protection during nutrient starvation stress. Therefore, we investigated the differences in the CI signatures of serum starved mouse atrial cardiomyocyte HL-1 cells treated with different drugs (Table 1). The β-blockers used in this study were Aten, Met, Car and Neb. In addition, we tested the effect of β-3 AR specific blocker SR59230A. To determine the effects of activating the Ang II receptors, we investigated how Ang II, the AT2R partial agonist CGP42112A (CGP), and a patent-pending novel peptide agonist of the AT2R named NP-6A4 (developed by Novopyxis Inc.) modulate CI. To further confirm the involvement of specific AngII receptors (AT1R or AT2R) we also used AT1R antagonist losartan (Lo) and AT2R antagonist PD123319 (PD) in conjunction with the agonists.

To further determine the contribution of cell viability and cell size to CI, we investigated changes in cell proliferation and viability of serum starved HL-1 in response to above drug treatments by MTS [3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4- sulfophenyl)-2H-tetrazolium] Cell Proliferation Assay. Changes in cell size of serum starved HL-1 in response to drug treatments were assessed by staining with Wheat germ agglutinin (WGA) conjugated with Alexa Fluor 647. To verify whether drug responses of mouse HL-1 cells, an immortalized cell line, could be translational in human cells, we examined changes in cell viability of primary cultures of hCAVSMCs in response to the above drug treatments by MTS Cell Proliferation Assay. We also determined changes in cell sizes of nutrient-stressed hCAVSMCs in response to drug treatments by staining with WGA conjugated with Alexa Fluor 647.

Myeloid Cell Leukemia 1 (MCL-1) is a protein that is essential for cell survival and viability of cardiomyocytes and VSMCs. Loss of MCL-1 in cardiac tissue results in cardiomyocyte disorganization, rapid heart failure and mitochondrial dysfunction [36–38]. MCL-1 is also implicated in VSMC survival [39]. Moreover, MCL-1 is required for cell adhesion [40]. We posited that increase in MCL-1 would improve viability of HL-1 and hCAVSMCs. Therefore, we investigated whether the drugs that were most effective in increasing the CI of HL-1 cells could also increase MCL-1 expression in HL-1 and hCAVSMCs.

Materials and Methods

Cell Culture and Reagents

Mouse atrial cardiomyocyte HL-1 cells were a gift from Dr. William Claycomb at Louisiana State University Medical Center. HL-1 cells were cultured at 37°C and 5% CO2 on surfaces pre-

---

Table 1. List of drugs used in this study and their targets.

| Drug Used  | Known Targets | Mode of Action |
|------------|---------------|---------------|
| Nebivolol  | β1 AR; β3 AR  | Antagonist; Agonist |
| Carvedilol | β1 and β2 AR  | Antagonist     |
| Metoprolol | β1 and β2 AR  | Antagonist     |
| Atenolol   | β1 and β2 AR  | Antagonist     |
| Angiotensin II | AT1R and AT2R | Agonist |
| CGP42112A  | AT2R          | Partial Agonist |
| NP-6A4     | AT2R          | Agonist       |
| Losartan   | AT1R          | Antagonist    |
| PD123319   | AT2R          | Antagonist    |
| SR59230A   | β3 AR         | Antagonist    |
| U73122     | Phospholipase C| Inhibitor     |

doi:10.1371/journal.pone.0144824.t001
treated with 12.5 μg/ml bovine fibronectin in 0.02% gelatin solution and grown in Claycomb medium supplemented with Fetal Bovine Serum (10%) (both from Sigma-Aldrich, St. Louis, MO), Penicillin/Streptomycin (100U/ml: 100mg/ml), Norepinephrine (100U/ml) and L-Glutamine (2mM) (GIBCO-Invitrogen) as described previously [38, 41]. hCAVSMCs were purchased from GIBCO-Invitrogen Cell culture (Carlsbad, CA) and were cultured according to manufacturer’s instructions at 37°C and 5% CO2 in Medium 231 supplemented with Smooth Muscle Growth Supplement (SMGS, Life Technologies, Cat. No. S-007-25). β-blockers Aten, Met and Car and Ang II were purchased from Sigma-Aldrich, and Neb was a gift from Forest Laboratories Inc. (New York). Losartan (AT1R inhibitor), PD123319 (AT2R inhibitor), CGP42112a (partial AT2R agonist), SR59230A (β-3 AR specific blocker), U73122 (Phospholipase C inhibitor) and isoproterenol (β-AR activator) were purchased from Tocris Bioscience (Bristol, UK); NP-6A4 was a gift from Novopyxis Inc. (Boston).

The xCELLigence RTCA and characterization of CI signatures of HL-1 cells
E-plates treated with fibronectin [38, 41] were used to seed HL-1 cells and to determine the changes in cell index readings in response to different drug treatments by RTCA DP Instrument (from ACEA Biosciences Inc.). A series of pilot studies were performed to determine the number of cells to be seeded and the time required for cell attachment before adding the drugs to obtain a consistent starting CI for all wells (data not shown). Based on the results of these pilot studies, we seeded 1.6 x 10^4 cells in each well of a 16-well E-plate in complete Claycomb Medium for all studies reported here and initiated monitoring of CI every 15 minutes. Cell attachment was assessed by stabilization of CI and confirmed by visualization under a light microscope (Nikon Eclipse TS1000). Once cells attached, wells were washed twice with serum-free medium and 95μL of serum-free medium was added to each well. CI was monitored at 5 min intervals to ensure that CI was stabilized before adding the drugs. Then, 5μL of each drug was added to achieve appropriate final concentrations. CI was monitored at every 5 min for the next 24 to 48 hours. Final concentrations for Aten, Met, Car, Neb and SR59230A (β-3 AR specific blocker) were 3μM since 3 μM was the lowest concentration used to show vasorelaxant activity of Neb and concentration of other β-blockers were kept 3μM for comparison [42]. Final concentrations for PD123319 and losartan were 1μM since we have previously shown effects of losartan and PD123319 at this concentration successfully [43]. Ang II, CGP42112A and NP-6A4 were used at a final concentration of 300nM since Ang II is often used at a final concentration of 300nM for vasoconstriction studies [44] and also to ensure that the concentration used is lower than that of the antagonists. Data reported is from a minimum of three independent E-plate experiments (different passages of HL-1 cells) and in each experiment, a given drug treatment was performed at least in triplicates and in wells at different locations to ensure that the data was not affected by positional effects.

Cell viability assay
MTS [3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium] Cell Proliferation Assay kit (Biovision Inc) was used according to the manufacturer’s instructions to determine the effects of different drugs on the cell viability of HL-1 cells and hCAVSMCs. HL-1 or hCAVSMC cells were seeded (5 x 10^3 cells/well) in 96 well plates in complete Claycomb medium [38] or Medium 231 supplemented with SMGS, respectively and all incubations were performed at 37°C in the presence of 5% CO2. After confirming that the cells were attached (as determined by light microscopy analysis), culture medium was removed and 200μL of serum-free Claycomb medium was added to HL-1 cells and 200μL of medium 231
without SMGS was added to CAVSMCs. Cells were then subjected to drug treatments by following a time course identical to those used for the xCELLigence RTCA. At the end of treatment, 20μL of MTS was mixed with culture medium and absorbance was measured at 30 min intervals at 490nm using the Synergy H4 Hybrid plate reader (BioTek, Vinooski, VT). Data is presented as the percentage of absorbance in drug treated cells compared to untreated cells.

**Immunofluorescence**

Immunofluorescence was used to determine the changes in the expression of MCL-1 in HL-1 cells and hCAVSMCs in response to different treatments. HL-1 cells and hCAVSMCs were grown on cover slips. All drug treatments were performed at least in triplicates and treatments were performed for six hours to match the time course in which we saw significant differences in the CI in response to drug treatments. Concentrations of drugs used for treatments were exactly the same as those used for xCELLigence RTCA analysis. After treatments with drugs, coverslips were washed with HEPES (Sigma), fixed with 4% paraformaldehyde for 15 min at room temperature, permeabilized with 0.5% Triton X-100, washed with HEPES buffer, and blocked with 1% bovine serum albumin (BSA) (Jackson ImmunoResearch), along with 10% goat serum (Sigma) in HEPES-T (1mL Tween-20/L). Coverslips were then incubated with anti-MCL-1 antibody (Abcam) (1:100 dilution, ~15 μg/ml) overnight at 4°C, washed with HEPES and then incubated with Alexa Fluor 488 goat anti-rabbit antibody (Invitrogen, Inc.) (1:200 dilution, 10 μg/ml) for 1 hour at room temperature. The coverslips were then washed with HEPES and mounted with Fluoroshield with DAPI (4',6-diamidino-2-phenylindole) (Sigma-Aldrich).

Wheat germ agglutinin (WGA) conjugated with Alexa Fluor 647 (Invitrogen, Inc.) was used to label HL-1 and hCAVSMC cell membranes and was used according to manufacturer’s instructions. HL-1 cells were grown on coverslips in the presence of Claycomb medium containing 0.5% FBS (HL-1) for 48 hours and then the drug treatments were performed for 6 and 24 hours. For hCAVSMCs, drug treatments were performed for 6 hours and the cells were maintained in Medium 231 without SMGS. At the end of treatments, cells were fixed and stained. Visualization was performed using a Leica DMI 4000B inverted confocal microscope using Leica Application Suite software. Imaging was done at 40x and 63x magnification using oil immersion. Fluorescence intensity and cell size measurement was done using ImageJ software (NIH, Bethesda, MD).

**Statistics**

Statistical analysis was performed using the SPSS 20 software package. Results are expressed as mean ± SEM (standard error of mean). Differences between groups were tested by using one-way ANOVA followed up with the Least Significant Difference (LSD) post-test or t-test, as appropriate, and two-tailed p-values are reported. A p-value of ≤ 0.05 was considered statistically significant.

**Results**

CI signature of nebivolol and carvedilol are different from that of atenolol and metoprolol

All β-blockers are known to inhibit cardiomyocyte apoptosis [7–10]. However, changes in CI over time in response to treatment with different β-blockers were not similar. HL-1 cells treated with Aten and Met exhibited a similar pattern of changes in CI and their CIs were lower by ~15% than the CI of untreated cells (Fig 1A). Changes in the CI of HL-1 cells treated with Car
exhibited an initial suppression followed by a recovery, however, overall, CI still remained lower by ~8% than that of untreated cells (Fig 1B). Neb-treated cells showed a much steeper reduction in CI (~20%) within the first 30 min of treatment followed by a recovery, but Neb treatment resulted in the lowest CI (~17%; Fig 1B). These data suggested that CI signatures generated by Neb and Car are unique and different from the CI signatures of Met or Aten. Conversely, isoproterenol (Isop), a standard selective β-adrenoceptor agonist, increased the CI immediately after addition when used at a concentration of 50nM and this increase (~22%) was maximum after 3 hours (Fig 1C). To determine the effect of inhibition of β3-AR, we treated HL-1 cells with SR59230A which also showed a reduction in CI (~15.5% at 6 hour time point) (Fig 1D). Moreover, exposure of HL-1 cells to a combination of SR59230A and Neb appears to increase the doubling time of the CI even further than either drug individually, indicating that the cell survival or growth was further impaired (Fig 1E). Collectively these data

Fig 1. Differences in the CI signatures of 2nd and 3rd generation β-Blockers, Isoproterenol, and the β3-AR Inhibitor SR59230A in serum-starved HL-1 cardiomyocytes. Cell Index (CI) data generated by Xcelligence RTCA when serum starved HL-1 cells were treated with different drugs for six hours are shown in graphs (A-D). All drugs except isoproterenol reduced the rate of increase in CI with time. Since all drugs were dissolved in Dimethyl sulfoxide (DMSO), control cells in this experiment received 0.05% DMSO (similar to the amount of DMSO in the drug preparation). (A) Changes in the CI of 2nd generation β-Blockers Aten (300 μM) and Met (300μM) were similar. (B) Changes in the CI of 3rd generation β-Blockers Neb and Car were different from that of the 2nd generation β-Blockers and also different from each other. A quick suppression (a dip) of CI was observed within 30 minutes of addition of these drugs. This was not observed with the 2nd generation β-Blocker treatments. Suppression of CI was more pronounced with Neb than Car indicating that each drug had unique CI signature. (C) Changes in CI in response to Isoproterenol (Isop) (added after one hour pre-treatment with Neb or Met). The red box indicates the time taken for addition of isoproterenol and the change in the pattern of graph due to the brief temperature change since the door was opened to add the drug. Isoproterenol increased CI initially compared to Con, however, after 2 hours, there was a reduction in CI. (D) Changes in CI in response to β3-AR inhibitor SR59230A exhibiting an initial sudden dip. Values are shown as means, n=4 and p<0.05 for all treatments compared to control for (A-D). (E) Combination of Neb and SR59230A increases CI doubling time compared to treatment by either drug alone, suggesting further suppression of cell growth. Values are means ± SEM for each point in the graphs, n = 4, *p<0.05 compared to control. All statistical significance determined by one-way ANOVA followed by the LSD post-hoc test.

doi:10.1371/journal.pone.0144824.g001
suggest that blocking of the β-ARs expressed by HL-1 cells have an inhibitory effect on their CI.

**Inhibition of phospholipase C reduces the CI of HL-1 cells**

Previous studies have shown that phospholipase Cγ is essential for cardiomyocyte survival under oxidative stress, and inhibition of phospholipase Cγ with U73122 increases apoptosis [43]. Since nutrient starvation can induce oxidative stress, we tested whether inhibition of phospholipase Cγ by U73122 in the serum-starved HL-1 cells results in cytotoxicity. Treatment of serum-starved HL-1 cells with U73122 suppressed their CI drastically (~94%) (Fig 2A). This observation suggests that inhibition of phospholipase Cγ under serum starvation promotes cytotoxicity and this can be detected by reduction in CI.

**Ang II increased CI of HL-1 cells and AT1R antagonist did not suppress this effect**

Ang II acting through AT1R promotes cell growth [22, 23, 29]. To determine the effects of Ang II on the CI unit signature of HL-1 cells, we investigated the changes in CI of HL-1 cells treated with Ang II (300nM) in the presence and absence of AT1R inhibitor losartan (1μM). The CI of HL-1 cells treated with Ang II was higher than that of untreated HL-1 cells (≥9.6%) and pre-treatment with losartan did not change this effect (Fig 2B). This data indicates that Ang II-induced increase in CI is not mediated through AT1R.

**Treatment with NP-6A4, a novel peptide agonist of AT2R, resulted in the highest increase in CI of HL-1 cells**

Since Ang II also activates the AT2R, to determine the effects of AT2R activation on the CI signature of HL-1 cells, we determined changes in CI of HL-1 cells treated with a partial AT2R agonist, CGP42112A [45], and a novel AT2R agonist, NP-6A4. NP-6A4 is a small peptide, anti-inflammatory drug that binds AT2R according to computational modeling and simulation (from Novopyxis, Inc. patent pending). Treatments with CGP42112A and NP-6A4 (300nM of each drug) showed a significant increase in the CI (CGP42112A: ≥14%, NP-6A4: ≥25%) of HL-1 cells (Fig 2C). NP-6A4 treatment resulted in the highest increase in CI of HL-1 cells by the 6

---

**Fig 2. Effect of phospholipase C inhibition and Angiotensin II Type 2 receptor (AT2R) activation on CI of serum-starved HL-1 cardiomyocytes.** (A) Treatment by PLC inhibitor U73122 resulted in a drastic drop in CI immediately after adding the drug. (B) Treatment by Angiotensin II (Ang II) increased CI compared to Con and pre-treatment with losartan (Lo), an AT1R antagonist did not reduce Ang II-induced increase in CI. Therefore, AT1R activation by Ang II is not responsible for Ang II induced increase in CI. (C) Treatment by AT2R specific agonists increased CI with magnitude of increase of CGP42112A>NP-6A4. CGP42112A is referred as CGP in the graphs. Since difference between CI of the control (treated with saline) and drugs was maximum at about 6 hours, the 6 hour time point was selected for final comparison shown in Fig D. Values are means ± SEM for each point in the graphs, n = 4, *p<0.05 compared to control for graphs A-C. (D) CI at 6-hour time-point showing pre-treatment by AT2R specific inhibitor PD123319 abolishes the effect of CGP42112A and NP-6A4; therefore, the CI increase by these agonists is mediated by AT2R. PD123319 is referred as PD in the graphs. Values are means ± SEM, n ≥ 4 and *p<0.05.

doi:10.1371/journal.pone.0144824.g002
hour time point (Fig 2C). To confirm that the NP-6A4-induced increase in CI of HL-1 cells is due to AT2R activation, we tested whether this effect is inhibited by the AT2R specific antagonist PD123319. Pre-treatment with 1μM of PD123319 inhibited increase in CI induced by CGP42112A and NP-6A4 (Fig 2D). These data suggest that AT2R activation results in an increase in CI of HL-1 cells and that NP-6A4 increases the CI of HL-1 cells by activating AT2R.

Changes in Cell size of HL-1 cells in response to drug treatments

To determine whether there was any difference in the cell sizes of HL-1 cells in response to drug treatments, we stained untreated and drug-treated cells with wheat germ agglutinin (WGA) and measured their size using ImageJ software (NIH, Bethesda, MD). Cells were initially made quiescent by growing them on coverslips in the presence of Claycomb medium containing 0.5% FBS for 48 hours and then the drug treatments were performed for a period of 6 and 24 hours [46]. WGA staining at the end of six-hour treatment showed that Neb significantly reduced cell size (~25%) while other drug treatments did not have a significant effect (Fig 3A–3C). However, when the drug treatments were extended for 24 hours, treatments with Met and Car also resulted in a significant reduction in cell size (Fig 3D and 3E). Treatment with Aten did not change cell size (Fig 3B and 3E). This observation suggested that changes in cell size could be one of the mechanisms for reduction in CI in response to treatments with Neb, Met and Car.

NP-6A4 improved cell viability of serum starved HL-1 cells

To determine the correlation between CI and cell viability of HL-1 cells, the MTS cell proliferation assay was used. When compared to untreated, serum starved HL-1 cells, treatment with
U73122 reduced cell viability (~20%) and this effect was statistically significant (Fig 4A). U73122 also decreased the CI of HL-1 cells drastically (Fig 2A). Thus, reduction in cell viability could, in part, account for the drastic reduction in CI of HL-1 cells by U73122. None of the β-blockers significantly changed the cell viability of serum starved HL-1 cardiomyocytes (Fig 4A). Thus, the suppression of CI induced by the β-blockers is not due to a reduction in cell viability, but rather other mechanisms. Interestingly, AT2R activation by NP-6A4 increased cell viability of serum starved HL-1 cells significantly when compared to untreated cells (Fig 4B). Therefore, increase in cell viability could have contributed to increase in CI by NP-6A4.

**NP-6A4 increased the expression of MCL-1 in HL-1 cells**

MCL-1 is a critical molecule for cardiomyocyte survival, since ablation of cardiac specific MCL-1 causes fatal heart failure and significant mitochondrial damage [36, 37]. We have recently reported that suppression of cardiac MCL-1 expression correlates with cardiomyocyte disarray in diabetic rats [38]. It is also known that MCL-1 may be important for cell adhesion [40]. Since CI is a measure of cell number, cell size and adhesion, and MCL-1 is involved in maintaining cell viability and adhesion, we posited that expression of MCL-1 would correlate with the CI. To determine whether MCL-1 expression in HL-1 cells correlated with the changes in their CIs in response to treatments with β-blockers and NP-6A4, we investigated the changes in MCL-1 expression in HL-1 cells subjected to treatment with these drugs. Drug treatments were performed for 6 hours since at this time point drug treatment yielded significant difference between the CI of drug-treated and vehicle-treated cells. As presented in Fig 5A and 5B, immunofluorescence analysis of MCL-1 expression and quantification using ImageJ (~50 cells per treatment) showed that treatments with all β-blockers suppressed MCL-1 expression significantly (Neb/C20 29%, Car/C20 25%, Met/C20 32% and Aten/C20 36%). Conversely, AT2R agonist NP-6A4 increased MCL-1 expression by ≥45% (Fig 5C). This effect was inhibited by the AT2R antagonist PD123319 (Fig 5C). Quantification of MCL-1 expression using ImageJ (~70 cells per treatment) showed that the NP-6A4-mediated increase in MCL-1 expression in HL-1 was significant (Fig 5D). Since NP-6A4-mediated increase in MCL-1 expression is suppressed by...
the AT2R antagonist PD123319 (Fig 5D), increase in MCL-1 expression by NP-6A4 is mediated by AT2R. There was no significant difference between the MCL-1 expression levels of DMSO-treated and PBS-treated control cells.

Effect of β-blockers on cell size and MCL-1 expression in hCAVSMCs

To determine whether the cell responses of mouse cardiomyocyte HL-1 cells to β-blockers are similar to that occur in other cardiovascular cells, we examined the changes in cell size and MCL-1 expression in primary cultures of nutrient-stressed hCAVSMCs in response to treatments with β-blockers. hCAVSMCs were nutrient-stressed via maintenance in Medium 231 without SMGS and then subjected to a 6-hour treatment with β-blockers as described for HL-1 cells. Immunofluorescence analysis using anti-MCL-1 antibody showed that MCL-1 expression was significantly suppressed in hCAVSMCs when exposed to Neb, Met and Aten (Fig 6A and 6B). Though treatment with Car also showed a trend towards suppression of MCL-1, this was not statistically significant. WGA staining showed that Neb was most effective in suppressing cell size in hCAVSMCs (~25%; n = 83 cells) (Fig 6C). Car also significantly reduced cell size (~23%; n = 74 cells). Treatment with Met also showed a trend towards reducing cell size, however this was not statistically significant (~13%; n = 108 cells). Aten treatment did not show
any reduction in cell size. Thus, Neb treatment was most effective in reducing cell size in both mouse HL-1 cells and primary cultures of hCAVSMCs.

NP-6A4 increased cell viability and expression of MCL-1 in primary cultures of hCAVSMCs

To determine whether NP-6A4 treatment could improve cell viability compared to β-blocker treatment in hCAVSMCs, we determined cell viability of nutrient-stressed hCAVSMCs in
response to treatments with NP-6A4 and 2nd and 3rd generation β-blockers by MTS cell proliferation assay. Treatments with β-blockers did not significantly affect cell viability of hCAVSMCs (Fig 7A). Only NP-6A4 significantly improved cell viability of hCAVSMCs among the drugs tested (Fig 7A). Determination of MCL-1 expression in hCAVSMCs and quantification using ImageJ (~25 cells per treatment) showed that NP-6A4 increased MCL-1 expression in these cells by ≥22% (Fig 7B and 7C). Thus, NP-6A4-mediated up-regulation of MCL-1 expression is a signaling mechanism present in both mouse cardiomyocyte HL-1 cells (Fig 5C and 5D) and primary culture of human CAVSMCs (Fig 7B and 7C).

Fig 7. Effect of β-Blockers and AT2R agonists on cell viability and effect of novel AT2R agonist NP-6A4 on MCL-1 expression in Human Coronary Artery Vascular Smooth Muscles Cells. (A) Graph shows data from CellTiter 96 AQueous one Solution Assay. Treatment with β-blockers did not significantly alter cell viability of hCAVSMCs while treatment with NP-6A4 resulted in the highest increase in the number of the viable cells. Data presented as means ± SEM, n=3 and *p<0.05 compared to control. (B) Representative images of immunofluorescence staining with anti-MCL-1 antibody and nuclear stain DAPI in hCAVSMCs in response to treatment by NP-6A4 (scale bars = 50 μm). (C) Quantification of MCL-1 expression in hCAVSMCs. Data is shown as means ± SEM, n=20 and *p<0.05 compared to control as determined by Student’s 2-tailed T-test. Thus, NP-6A4 mediated increase in MCL-1 expression is a common signaling mechanism in mouse HL-1 cardiomyocytes and hCAVSMCs.

doi:10.1371/journal.pone.0144824.g007
Discussion

Nutrient starvation underlies cell death associated with ischemic heart disease, the leading cause of death worldwide [1–4]. Previous studies have shown that β-blockers are effective in mitigating cardiomyocyte apoptosis and they are the standard of care to reduce infarct size after cardiac ischemia. Aten and Met are 2nd generation cardioselective β-blockers that reduce cardiomyocyte apoptosis caused by conditions such as coronary microembolization and exposure to lipopolysaccharides (LPS) [7, 8]. Car and Neb are 3rd generation β-blockers with additional vasodilative effects [9, 10, 17]. However, differences in their impact on cell survival under nutrient starvation are not fully elucidated. We took advantage of the powerful xCELLigence RTCA system that can generate a CI signature that captures minute changes in the physical properties of cells such as size and adhesion as well as cell growth for each drug to investigate their effects [47]. Data presented here suggest that the CI signatures of Neb and Car are different from those of Aten and Met, and also different from each other. This is not surprising since Neb and Car are structurally different from the 2nd generation drugs Aten and Met [9, 17]. Neb is also different from Car in that it is the only β-blocker that is both highly β1-selective, promotes endothelium-dependent vasodilation and also activates β3-AR [10, 17]. Thus the observation that they have unique CI signatures is in agreement with their differential structural and functional properties. Importantly, inhibition of any of the β-ARs resulted in the suppression of CI of HL-1 cells and this effect was exacerbated in response to double blockade of β-1 AR and β-3 AR. Therefore, CI serves as a useful physical measurement to determine the welfare of the cell in nutrient starvation. Previous studies have shown that reduction in CI correlates with poor cell survival [47]. Indeed treatment with phospholipase C inhibitor U73122, that is reported to increase apoptosis, was a powerful suppressor of CI in HL-1 cells in this study. The MTS cell proliferation assay did not show a significant suppression of cell viability (or growth) by any of the β-blockers and the extent of reduction in cell viability in response to U73122 assessed by MTS assay was lower compared to the extent of reduction of CI. Therefore, CI was more sensitive than the MTS assay in identifying the toxic effect of U73122 on HL-1 cardiomyocytes.

Consistent with the observation that β-blockers reduce apoptosis of cardiomyocytes, we did not see any significant changes in the cell viability of mouse HL-1 cardiomyocytes or human CAVSMCs with different β-blockers in the MTS cell proliferation assay. However, inhibition of phospholipase Cγ by U73122 significantly suppressed cell viability in hCAVSMCs. Thus, cell viability responses of mouse cardiomyocyte HL-1 cells and human CAVSMCs to β-blockers and U73122 were similar. Except Aten, other β-blockers reduced cell size of both HL-1 cells and hCAVSMCs. Since cell size is an important component of CI, we posit that reduction in cell size could have contributed to the reduction in CI induced by Neb, Met and Car.

Importantly, AT2R activation increased CI of serum-starved HL-1 cells. Ang II-mediated increase in CI was not suppressed by AT1R antagonist losartan, but was suppressed by AT2R antagonist PD123319. Both partial AT2R agonist CGP42112A and novel AT2R agonist NP-6A4 improved CI of serum starved HL-1 cells. Interestingly, NP-6A4 was more effective than CGP42112A in increasing the CI of serum-starved HL-1 cells (increase in CI:CGP42112A (≥14%), NP-6A4 (≥25%)) while pretreatment with PD123319 inhibited NP-6A4-induced increase in CI. MTS assay further showed that NP-6A4 rendered a significant increase in cell viability to both mouse HL-1 and human CAVSMC cells. Thus, NP-6A4, acting through AT2R, improved cell survival of both mouse cardiomyocyte HL-1 cells and human CAVSMCs more effectively than all other drugs tested here.

MCL-1 is critical for cardiomyocyte survival under stress and prevents vascular smooth muscle apoptosis [36–38]. Our results show that β-blockers suppress MCL-1 expression in
HL-1 cells. MCL-1 may play a role in cell adhesion since it was reported that deletion of Mcl-1 could cause peri-implantation embryonic lethality and Mcl-1 −/− blastocysts failed to attach in vitro [40]. Therefore, we speculate that suppression of MCL-1 by β-blockers during the 6-hour treatment could have resulted in partial suppression of HL-1 cell adhesion and this effect could have contributed to the β-blocker-induced reduction in the CI. Interestingly, AT2R agonist NP-6A4 was very effective in increasing MCL-1 expression in HL-1 cells as detected by immunofluorescence (Fig 5). Since MCL-1 promotes cell survival, regulation of MCL-1 expression by β-blockers and NP-6A4 may also be a contributing factor to the change in CI caused by these drugs. The observation that the AT2R agonist PD123319 inhibited the NP-6A4-induced increase in MCL-1 expression is consistent with the idea that NP-6A4 acts via AT2R to increase in MCL-1 expression. To date, there are no studies that show AT2R is a positive regulator of cardioprotective MCL-1. Comparison of the effects of β-blockers versus NP-6A4 of on cell viability and MCL-1 expression in human CAVSMCs and mouse cardiomyocyte HL-1 cells by β-blockers and AT2R agonists is summarized in Table 2.

The AT2R partial agonist CGP42112A did not significantly increase MCL-1 in HL-1 cells. We have shown previously that interaction of CGP42112A with AT2R is different from that of Ang II [48, 49]. Mutation of Asp297 in the 3rd extracellular loop abolished Ang II binding to the AT2R, but only partially reduced CGP42112A binding to the AT2R [48]. Similarly, truncation of C-terminus of the AT2R actually increased the affinity of CGP42112A whereas it partially suppressed the affinity of Ang II to the AT2R [49]. Since NP-6A4 increased MCL-1 expression and CGP42112A was not effective in this signaling, we propose that the mode of action of NP-6A4 is different from that of CGP42112A. Our observation that NP-6A4 could increase MCL-1 expression in human CAVSMC indicates that AT2R-mediated activation of MCL-1 expression is a mechanism that exists in both mouse and human cells. NP-6A4 is a patent-pending drug from Novopyxis Inc., and its pharmacological properties are not characterized. However, our results strongly suggest that NP-6A4 exerts its effects via AT2R and promotes cardiovascular cell survival under nutrient stress effectively.

One limitation of this study is that HL-1 cells do not represent all features of primary cultures of cardiomyocytes since HL-1 is an immortalized cell line. Additional studies are needed to determine whether NP-6A4 is capable of activating the AT2R-MCL-1 axis in primary cultures of human cardiomyocytes. However, our observation that NP-6A4 increases MCL-1

Table 2. Comparison of the effects of cardioprotective drugs used in this study on cell index, cell viability and MCL-1 expression of cardiomyocytes.

| Drugs and doses | Targets | CI (HL-1) | Viability (%) | MCL-1 (%) |
|----------------|---------|-----------|---------------|-----------|
|                |         | *H1-1*    | hCAVSMC       | *H1-1*    | hCAVSMC   |
| Nebivolol, 3μM | β1 AR; β3 AR | Lower, with dip | *96%* | *96%* | *71%* | *87%* |
| Carvedilol, 3μM | β1 and β2 AR | Lower, with dip | *93%* | *98%* | *75%* | *92%* |
| Metoprolol, 3μM | β1 and β2 AR | Lower | *93%* | – | *68%* | *80%* |
| Atenolol, 3μM | β1 and β2 AR | Lower | *104%* | *100%* | *64%* | *64%* |
| Ang II 300nM | AT1R & AT2R | Higher | *110%* | – | – | – |
| CGP42112A, 300nM | AT2R | Higher | *107%* | *114%* | *95%* | – |
| NP-6A4, 300nM | AT2R | Highest | *120%* | *120%* | *125%* | *123%* |

*Not statistically significant

*P<0.05

doi:10.1371/journal.pone.0144824.t002
expression in hCAVSMCs implies that NP-6A4-mediated improved survival of cardiovascular cells during nutrient stress could be a common mechanism in mouse and human cells. In this study, our focus was on identifying the subtle differences between different cardioprotective drugs in improving cell survival. Apart from nutrient stress, hypoxia is another major component of ischemia-associated cell death [50, 51]. During hypoxia, mitochondria act as oxygen sensors and contribute to the cell redox potential, ion homeostasis, and energy production [51]. Since MCL-1 is known to localize to the mitochondrial matrix and couples mitochondrial fusion to respiration, it is conceivable that a drug that could promote MCL-1 expression such as NP-6A4 could be protective for cardiovascular cells in hypoxia stress. Additional studies are needed to determine whether NP-6A4 mediated up-regulation of MCL-1 would have cardiovascular protective effects in conditions of hypoxia.

Conclusion

Loss of cell viability is a critical factor in cardiac damage resulting from ischemia. Stress caused by nutrient starvation is one of the critical components of ischemia-associated complications. Although there are several cardioprotective drugs that can reduce cell death, mechanisms by which they impact viability of cells dealing with nutrient starvation is not fully elucidated. Identifying the best drug that can promote cell viability during nutrient starvation will provide valuable insight into enabling reduction of cardiac damage. In this study we used cell index (CI) determination by the Xcelligence Real-Time Cell Analyzer (RTCA) as a method to uncover differences between widely used, and novel, cardioprotective drugs on mouse cardiomyocyte HL-1 cell survival subjected to a short term (6 hour) nutrient starvation. Data presented here show that 2nd and 3rd generation β-blockers have unique CI signatures and that all of them reduce rate of change in CI with time. It was interesting to note that Met, Car and Neb could reduce cell size of HL-1 cells and hCAVSMCs. Moreover, β-blockers also reduced expression of cardiovascular protective MCL-1 in HL-1 cardiomyocytes and hCAVSMCs. Thus, reduction in cell size and/or MCL-1 expression could have contributed to the reduction in CI of HL-1 cells caused by β-blockers. Conversely, Ang II increased the rate of change in CI with time and this effect was not mediated via the AT1R, but via the AT2R. Importantly, we show that a novel AT2R agonist NP-6A4 was most effective in increasing CI, cell viability, and expression of the anti-apoptotic protein MCL-1 in HL-1 cardiomyocytes. These data show for the first time that AT2R activation increases anti-apoptotic MCL-1 in cardiomyocytes. Interestingly, the partial agonist CGP42112A was not effective in increasing MCL-1 in cardiomyocytes. Collectively, these data suggest that NP-6A4-mediated AT2R activation is more protective for cardiomyocytes during nutrient starvation compared to other drugs tested in this study. Finally, these results also confirm that AT2R-mediated increase in MCL-1 expression by NP-6A4 (the AT2R-MCL-1 axis) also occurs in human CAVSMCs. Thus, the AT2R-MCL-1 axis is a common protective mechanism that improves cell viability in mouse and human cardiovascular cells.

Author Contributions

Conceived and designed the experiments: LP. Performed the experiments: AM. Analyzed the data: AM LP. Contributed reagents/materials/analysis tools: LP. Wrote the paper: AM LP.

References

1. World health Organization (2014). The top 10 causes of death. http://www.who.int/mediacentre/factsheets/fs310/en/
2. Center for Disease Control and Prevention Fact Sheets (Feb 6th 2015). Leading Causes of Death. http://www.cdc.gov/nchs/fastats/leading-causes-of-death.htm

3. Ong SB, Samangouei P, Kalkhoran SB, Hausenloy DJ. The mitochondrial permeability transition pore and its role in myocardial ischemia reperfusion injury. J Mol Cell Cardiol. 2015 Jan; 78:23–34 doi: 10.1016/j.yjmcc.2014.11.005 PMID: 25446182

4. Badalzadeh R, Mokhtari B, Yavari R. Contribution of apoptosis in myocardial reperfusion injury and loss of cardioprotection in diabetes mellitus. J Physiol Sci. 2015 May; 65(3):201–15 doi: 10.1007/s12576-015-0365-8 PMID: 25726180

5. Gatica D, Chiong M, Lavandero S, Kliosky DJ. Molecular mechanisms of autophagy in the cardiovascular system. irc Res. 2015 Jan 30; 116(3):456–67

6. Hashem SI, Perry CN, Bauer M, Han S, Clegg SD, Ouyang K et al. Oxidative Stress Mediates Cardiomyocyte Apoptosis in a Human Model of Danon Disease and Heart Failure. Stem Cells. 2015 Jul; 33 (7):2343–50. doi: 10.1002/stem.2015 PMID: 25826782

7. Su Q, Li L, Liu YC, Zhou Y, Lu YG, Wen WM. Effect of metoprolol on myocardial apoptosis and caspase-9 activation after coronary microembolization in rats. Exp Clin Cardiol. 2013 Spring; 18(2):161–5. PMID: 23940444

8. Wang Y, Wang Y, Yang D, Yu X, Li H, Lv X et al. β1-adrenoceptor stimulation promotes LPS-induced cardiomyocyte apoptosis through activating PKA and enhancing CaMKII and IkBα phosphorylation. Crt Care. 2015 Mar 9; 19(1):76.

9. Keating GM, Jarvis B. Carvedilol: a review of its use in chronic heart failure. Drugs. 2003; 63(16):1697–741. PMID: 12904089

10. Zhang Z, Ding L, Jin Z, Gao G, Li H, Zhang L et al. Nebivolol protects against myocardial infarction injury via stimulation of beta 3-adrenergic receptors and nitric oxide signaling. PLoS One. 2014 May 21; 9(5):e98179 doi: 10.1371/journal.pone.0098179 PMID: 24849208

11. Sato M, Engelman RM, Otani H, Maulik N, Rousou JA, Flack JE 3rd, et al. Myocardial protection by preconditioning of heart with losartan, an angiotensin II type 1-receptor blocker: implication of bradykinin-dependent and bradykinin-independent mechanisms. Circulation. 2000 Nov 7; 102(19 Suppl 3):III346–51. PMID: 11082412

12. Blessberger H, Kammler J, Domanovits H, Schlager O, Han S, Clegg SD, Ouyang K et al. Perioperative β-blockers for preventing surgery-related mortality and morbidity. Cochrane Database Syst Rev. 2014 Sep 18; 9:CD004476. doi: 10.1002/14651858.CD004476.pub2 PMID: 25230308

13. Amann U, Kirchberger I, Heier M, Golüke H, von Scheidt W, Kuch B, et al. Long-term survival in patients with different combinations of evidence-based medications after incident acute myocardial infarction: results from the MONICA/KORA Myocardial Infarction Registry. Clin Res Cardiol. 2014 Aug; 103 (8):655–64. doi: 10.1007/s00392-014-0688-0 PMID: 24604524

14. Thompson PL. Should β-blockers still be routine after myocardial infarction? Curr Opin Cardiol. 2013 Jul; 28(4):399–404. doi: 10.1097/HCO.0b013e32836e97a PMID: 23703252

15. Grimm C, Köberlein J, Wiosna W, Kiencke P, Rychlik R. New-onset diabetes and angiotensin-enzyme inhibitors on development of new-onset diabetes mellitus in patients with stable coronary artery disease. Am J Cardiol. 2011 Jun 15; 107(12):1705–9 doi: 10.1016/j.amjcard.2011.01.064 PMID: 21507365

16. Vardeny O, Uno H, Braunwald E, Rouleau JL, Gersh B, Maggioni AP et al. Prevention of Events with an β-blocker Nebivolol Is a GRK/β-arrestin biased agonist. PLoS One. 2013 Aug 20; 8(8):e71980. doi: 10.1371/journal.pone.0071980 PMID: 23977191

17. Gupta S, Wright HM. Nebivolol: a highly selective beta1-adrenergic receptor blocker that causes vaso-dilation by increasing nitric oxide. Cardiovasc Ther. 2008 Fall; 26(3):189–202 doi: 10.1111/j.1755-5922.2008.00054.x PMID: 18786089

18. Erickson CE, Gul R, Blessing CP, Nguyen J, Liu T, Pulakat L et al. The β-blocker Nebivolol Is a GRK/β-arrestin biased agonist. PLoS One. 2013 Aug 20; 8(8):e71980. doi: 10.1371/journal.pone.0071980 PMID: 23977191

19. Gul R, Demarco VG, Sowers JR, Whaley-Connell A, Pulakat L. Regulation of Overnutrition-Induced Cardiotoxic Mechanisms. Cardiorenal Med. 2012 Aug; 2(3):225–233. PMID: 22969779

20. Ladage D, Reidenbach C, Rieckeheer E, Graf C, Schwinger RH, Brixius K. Nebivolol lowers blood pressure and increases weight loss in patients with hypertension and diabetes in regard to age. J Cardiovasc Pharmacol. 2010 Sep; 56(3):275–81. PMID: 20571428 doi: 10.1097/FJC.0b013e3181eb4ff2

21. Gul R, Mahmood A, Luck C, Lum-Naihe K, Alfadda AA, Speth RC et al. Regulation of cardiac miR-208a, an inducer of obesity, by Rapamycin and Nebivolol. Obesity (Silver Spring). 2015 Nov; 23 (11):2251–9
22. Gul R, Ramdas M, Mandavia C, Sowers JR and Pulakat L. RAS-mediated adaptive mechanisms in cardiovascular tissues: Confounding factors of RAS blockade therapy and alternative approaches. 2012. Cardiores Med, (4):268–280.

23. Akazawa H, Yabumoto C, Yano M, Kudo-Sakamoto Y, Komuro I. ARB and cardioprotection. Cardiovasc Drugs Ther. 2013 Apr; 27(2):155–60 doi: 10.1007/s10557-012-6392-2 PMID: 22538956

24. Kajstura J, Cigola E, Malhotra A, Li P, Cheng W, Meggs LG et al. Angiotensin II induces apoptosis of adult ventricular myocytes in vitro. J Mol Cell Cardiol 1997, 29:859–870. PMID: 9152847

25. Yang C, Liu Z, Liu K, Yang P. Mechanisms of Ghrelin anti-heart failure: inhibition of Ang II-induced cardiomyocyte apoptosis by down-regulating AT1R expression. PLoS One. 2014 Jan 21; 9(1):e85785 doi:10.1371/journal.pone.0085785 PMID: 24465706

26. Strauss MH, Hall AS. Angiotensin receptor blockers may increase risk of myocardial infarction: unraveling the ARB-MI paradox. Circulation. 2006 Aug 22; 114(8):838–54. PMID: 16923768

27. Altarche-Xifré W, Curato C, Kaschina E, Grzesiak A, Slavic S, Dong J, et al. Cardiac c-kit+AT2+ cell population is increased in response to ischemic injury and supports cardiomyocyte performance. Stem Cells. 2009 Oct; 27(10):2488–97 doi: 10.1002/stem.171 PMID: 19591228

28. Ludwig M, Steinhoff G, Li J. The regenerative potential of angiotensin AT2 receptor in cardiac repair. Can J Physiol Pharmacol. 2012 Mar; 90(3):287–93. doi: 10.1139/y11-108 PMID: 22364522

29. Kumar V, Knowle D, Gavini N, Pulakat L. Identification of the region of AT2 receptor needed for inhibition of the AT1 receptor-mediated inositol 1,4,5-triphosphate generation. FEBS Lett. 2002 Dec 18; 532 (3):379–86. PMID: 12482596

30. Kajstura J, Cigola E, Malhotra A, Li P, Cheng W, Meggs LG, et al. Angiotensin II induces apoptosis of adult ventricular myocytes in vitro. J Mol Cell Cardiol. 1997 Mar; 29(3):859–70 PMID: 9152847

31. Sugino H, Ozono R, Kurisu S, Matsuura H, Ishida M, Oshima T et al. Apoptosis is not increased in myocardium overexpressing type 2 angiotensin II receptor in transgenic mice. Hypertension. 2001 Jun; 37 (6):1394–8. PMID: 11408383

32. Troncoso R, Vicencio JM, Parra V, Nemchenko A, Kawashima Y, Del Campo A et al. Energy-preserving effects of IGF-1 antagonist starvation-induced cardiac autophagy. Cardiovasc Res. 2012 Feb 1; 93 (2):320–9 doi: 10.1093/cvr/cvr321 PMID: 22135164

33. Ma X, Liu H, Foyil SR, Godar RJ, Weinheimer CJ, Hill JA et al. Impaired autophagosome clearance contributes to cardiomyocyte death in ischemia/reperfusion injury. Circulation. 2012 Jun 26; 125 (25):3170–81 doi: 10.1161/CIRCULATIONAHA.111.041814 PMID: 22592897

34. Ke N, Nguyen K, Irelan J, Abassi YA. Multidimensional GPCR profiling and screening using impedance-based label-free and real-time assay. Methods Mol Biol. 2015; 1272:215–26. doi: 10.1007/978-1-4939-2336-6_15 PMID: 25563187

35. Ramis G, Martínez-Alarcón L, Quereda JJ, Mendonça L, Majado MJ, Gomez-Coelho K et al. Optimization of cytotoxicity assay by real-time, impedance-based cell analysis. Biomed Microdevices. 2013 Dec; 15(6):985–95 doi: 10.1007/s10557-013-9790-8 PMID: 23876814

36. Thomas RL, Roberts DJ, Kubil DA, Lee Y, Quinsay MN, Owens JB et al. Loss of MCL-1 leads to impaired autophagy and rapid development of heart failure. Genes Dev. 2013 Jun 15; 27(12):1365–77 doi: 10.1101/gad.215871.113 PMID: 23788622

37. Wang X, Bathina M, Lynch J, Koss B, Calabrese C, Frase S, Schuetz JD et al. Deletion of MCL-1 causes lethal cardiac failure and mitochondrial dysfunction. Genes Dev. 2013 Jun 15; 27(12):1351–64 doi:10.1101/gad.215855.113 PMID: 23788622

38. Arnold N, Koppula PR, Gul R, Luck C, Pulakat L. Regulation of cardiac expression of the diabetic marker microRNA miR-29. PLoS One. 2014 Jul 25; 9(7):e103284 doi:10.1371/journal.pone.0103284 PMID: 25062042

39. Ibe JC, Zhou Q, Chen T, Tang H, Yuan JX, Raj JU et al. Adenosine monophosphate-activated protein kinase is required for pulmonary artery smooth muscle cell survival and the development of hypoxic pulmonary hypertension. Am J Respir Cell Mol Biol. 2013 Oct; 49(4):609–18 doi: 10.1165/rcmb.2012-0460OC PMID: 23668615

40. Rinkenberger JL, Horning S, Klocke B, Roth K, Korsmeyer SJ. Mcl-1 deficiency results in peri-implantation embryonic lethality. Genes Dev. 2000 Jan 1; 14(1):23–7 PMID: 10640272

41. White SM, Constantin PE, Claycomb WC. Cardiac physiology at the cellular level: use of cultured HL-1 cardiomyocytes for studies of cardiac muscle structure and function. Am J Physiol Heart Circ Physiol 2004; 286: H823–H829. PMID: 14766671

42. Parenti A, Filippi S, Amerini S, Granger HU, Fazzini A, Ledda F. Inositol phosphate metabolism and nitric-oxide synthase activity in endothelial cells are involved in the vasorelaxant activity of nebrov. J Pharmacol Exp Ther. 2000 Feb; 292(2):698–703. PMID: 10640308
43. Mangat R, Singal T, Dhall NS, Tappia PS. Inhibition of phospholipase C-gamma 1 augments the
decrease in cardiomyocyte viability by H2O2. Am J Physiol Heart Circ Physiol. 2006 Aug; 291(2):H854–60. PMID: 16501016

44. Xiao L, Haack KK, Zucker IH. Angiotensin II regulates ACE and ACE2 in neurons through p38 mitogen-activated protein kinase and extracellular signal-regulated kinase 1/2 signaling. Am J Physiol Cell Physiol. 2013 Jun 1; 304(11):C1073–9 doi: 10.1152/ajpcell.00364.2012 PMID: 23535237

45. Falcón BL, Veerasingham SJ, Sumners C, Raizada MK. Angiotensin II type 2 receptor-mediated gene expression profiling in human coronary artery endothelial cells. Hypertension. 2005 Apr; 45(4):692–7 PMID: 15710780

46. Brunt KR, Tsuji MR, Lai JH, Kinobe RT, Durante W, Claycomb WC et al. Heme Oxygenase-1 Inhibits Pro-Oxidant Induced Hypertrophy in HL-1 Cardiomyocytes. Experimental biology and medicine (Maywood, NJ). 2009; 234(5):582–594.

47. Ke N, Wang X, Xu X, Abassi YA. The xCELLigence system for real-time and label-free monitoring of cell viability. Methods Mol Biol. 2011; 740:33–43 doi: 10.1007/978-1-61779-108-6_6 PMID: 21468966

48. Knowle D, Kurfis J, Gavini N, Pulakat L. Role of Asp297 of the AT2 receptor in high-affinity binding to different peptide ligands. Peptides. 2001 Dec; 22(12):2145–9 PMID: 11786202

49. Pulakat L, Gray A, Johnson J, Knowle D, Burns V, Gavini N. Role of C-terminal cytoplasmic domain of the AT2 receptor in ligand binding and signaling. FEBS Lett. 2002 Jul 31; 524(1–3):73–8. PMID: 12135744

50. Solaini G, Baracca A, Lenaz G, Sgarbi G. Hypoxia and mitochondrial oxidative metabolism. Biochim Biophys Acta. 2010 Jun-Jul; 1797(6–7):1171–7 doi: 10.1016/j.bbapro.2010.02.011 PMID: 20153717

51. Percivalle RM, Stewart DP, Koss B, Lynch J, Mliasta S, Bathina M et al. Anti-apoptotic MCL-1 localizes to the mitochondrial matrix and couples mitochondrial fusion to respiration. Nat Cell Biol. 2012 Apr 29; 14(6):575–83. doi: 10.1038/ncb2488 PMID: 22544066